Trial Profile
An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Degarelix; Degarelix; Goserelin; Goserelin; Histrelin; Histrelin; Leuprorelin; Leuprorelin; Triptorelin; Triptorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 28 Apr 2023 Planned End Date changed from 10 Apr 2023 to 10 Apr 2024.
- 26 Apr 2022 Planned End Date changed from 1 Mar 2020 to 10 Apr 2023.
- 24 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.